West Pharmaceutical Services (WST) Other Non-Current Liabilities (2009 - 2026)

West Pharmaceutical Services' Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $87.6 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 33.33% year-over-year to $87.6 million; the TTM figure through Mar 2026 stood at $87.6 million (up 33.33% YoY), while the FY2025 annual figure was $75.2 million, up 20.9% from the prior year.
• Other Non-Current Liabilities came in at $87.6 million for Q1 2026 at West Pharmaceutical Services, up from $75.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $87.6 million in Q1 2026 to a low of $33.9 million in Q3 2022.
• A 5-year average of $59.2 million and a median of $58.5 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 62.54% in 2023 and gained 3.76% in 2024, its largest moves.
• West Pharmaceutical Services' Other Non-Current Liabilities stood at $51.6 million in 2022, then gained by 13.37% to $58.5 million in 2023, then climbed by 6.32% to $62.2 million in 2024, then increased by 20.9% to $75.2 million in 2025, then gained by 16.49% to $87.6 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $87.6 million, $75.2 million, and $75.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison